Summary:
- This article discusses the latest developments in BridgeBio Pharma's oncology pipeline, particularly their progress with their RAS-targeted therapies.
- BridgeBio has highlighted the promising response rates and tolerability of their lead RAS-targeted drug candidate, BBO-8520, both as a standalone treatment and in combination with other therapies.
- The article suggests that BridgeBio's RAS-targeted pipeline could be a significant advancement in the field of cancer treatment, as RAS mutations are a common driver of various cancer types.